Trial · NCT03556761

Furosemide for Accelerated Recovery of Blood Pressure Postpartum

NCT03556761, Phase 2, Completed, University of Pennsylvania; results first posted 2020-09-10

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Furosemide for Accelerated Recovery of Blood Pressure Postpartum. Trials, record NCT03556761. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03556761

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Furosemide for Accelerated Recovery of Blood Pressure Postpartum
NCT number: NCT03556761
Status: Completed
Phases: Phase 2
Enrollment: 384 participants, actual
Lead sponsor: University of Pennsylvania
Conditions: Hypertension, Pregnancy-Induced
Interventions: Oral furosemide, Placebo Oral Tablet
First posted: 2018-06-14
Last updated: 2020-09-10
Results first posted: 2020-09-10

Source ClinicalTrials.gov

Registered outcomes8

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Persistently Elevated Blood Pressures 7 Days Postpartum	0-7 days postpartum	To compare the rate of persistently elevated blood pressures (\>140/90) in women that receive a five day furosemide course compared to those that receive placebo.
Primary	Time to Resolution	0-14 days postpartum	To compare the time (days) required to achieve a resolution of elevated blood pressure, adjusted for mode of delivery.
Secondary	Postpartum Readmission	0-6 weeks postpartum	Number of subjects with one or more readmission/ER visit that were hypertension related
Secondary	Number of Subjects Who Had Severe Hypertension Postpartum	0-6 weeks postpartum	Number of women who had severe hypertension (systolic blood pressure\>160 millimeters of mercury or diastolic blood pressure\>110 millimeters of mercury) postpartum
Secondary	Postpartum Length of Stay	0-6 weeks postpartum	Number of days postpartum participants stayed in the hospital
Secondary	Subjects With Complications During Hospitalization	0-6 weeks postpartum	Subjects with complications during hospitalization related to hypertensive disorders of pregnancy.
Secondary	Number of Subjects Experiencing One or More Adverse Effects	0-6 weeks postpartum	Number of subjects experiencing one or more adverse effects secondary to furosemide
Secondary	Number of Subjects That Required for Additional Antihypertensives	0 to 6 weeks post-partum	Number of subjects that required additional hypertensive medication after discharge

Source ClinicalTrials.gov

Outcomes8

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Persistently Elevated Blood Pressures 7 Days Postpartum	0-7 days postpartum	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Time to Resolution	0-14 days postpartum	days	MEDIAN
SECONDARY	Postpartum Readmission	0-6 weeks postpartum	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Subjects Who Had Severe Hypertension Postpartum	0-6 weeks postpartum	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Postpartum Length of Stay	0-6 weeks postpartum	Days	MEDIAN
SECONDARY	Subjects With Complications During Hospitalization	0-6 weeks postpartum	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Subjects Experiencing One or More Adverse Effects	0-6 weeks postpartum	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Subjects That Required for Additional Antihypertensives	0 to 6 weeks post-partum	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Persistently Elevated Blood Pressures 7 Days Postpartum	Oral Furosemide	10		Participants
Persistently Elevated Blood Pressures 7 Days Postpartum	Placebo Oral Tablet	23		Participants
Time to Resolution	Oral Furosemide	10	Inter-Quartile Range 6.25 to 12.5	days
Time to Resolution	Placebo Oral Tablet	10.5	Inter-Quartile Range 6.5 to 12.5	days
Postpartum Readmission	Oral Furosemide	9		Participants
Postpartum Readmission	Placebo Oral Tablet	16		Participants
Number of Subjects Who Had Severe Hypertension Postpartum	Oral Furosemide	81		Participants
Number of Subjects Who Had Severe Hypertension Postpartum	Placebo Oral Tablet	86		Participants
Postpartum Length of Stay	Oral Furosemide	2	Inter-Quartile Range 2 to 3	Days
Postpartum Length of Stay	Placebo Oral Tablet	2	Inter-Quartile Range 2 to 2	Days

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Oral Furosemide	192
Overall Study	STARTED	Placebo Oral Tablet	192
Overall Study	COMPLETED	Oral Furosemide	168
Overall Study	COMPLETED	Placebo Oral Tablet	163
Overall Study	NOT COMPLETED	Oral Furosemide	24
Overall Study	NOT COMPLETED	Placebo Oral Tablet	29

Source ClinicalTrials.gov

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Pulmonary edema	Pregnancy, puerperium and perinatal conditions	Oral Furosemide	3	192	3
other	Pulmonary edema	Pregnancy, puerperium and perinatal conditions	Placebo Oral Tablet	1	192	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Oral Furosemide	0	192
Total, all-cause mortality	Placebo Oral Tablet	0	192
Total, other adverse events	Oral Furosemide	3	192
Total, other adverse events	Placebo Oral Tablet	1	192
Total, serious adverse events	Oral Furosemide	0	192
Total, serious adverse events	Placebo Oral Tablet	0	192

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
33550824	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons8

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Oral Furosemide vs Placebo Oral Tablet: Persistently Elevated Blood Pressures 7 Days Postpartum	Trial comparisons
Oral Furosemide vs Placebo Oral Tablet: Number of Subjects Who Had Severe Hypertension Postpartum	Trial comparisons
Oral Furosemide vs Placebo Oral Tablet: Postpartum Readmission	Trial comparisons
Oral Furosemide vs Placebo Oral Tablet: Subjects With Complications During Hospitalization	Trial comparisons
Oral Furosemide vs Placebo Oral Tablet: deaths from any cause	Trial comparisons
Oral Furosemide vs Placebo Oral Tablet: Number of Subjects That Required for Additional Antihypertensives	Trial comparisons
Oral Furosemide vs Placebo Oral Tablet: Number of Subjects Experiencing One or More Adverse Effects	Trial comparisons
Oral Furosemide vs Placebo Oral Tablet: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03556761

GET https://conductscience.org/api/trials/v1/NCT03556761/registered

API reference For AI assistants